Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

  • End date
    Dec 31, 2026
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 4 October 2022
chemotherapy regimen
nasopharyngeal carcinoma


Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy. After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be given by IMRT, under the dose of GTVnx 68-70Gy/30-33f, 5d/w,6-7w, during which, every patient would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease progression or intolerance of treatment. . We aim to evaluate the three years progression free survival of these patients by the combination of Envafolimab with curative chemoradiotherapy.

Condition Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy, PD-L1
Treatment Envafolimab Plus Chemoradiotherapy
Clinical Study IdentifierNCT05397769
SponsorSun Yat-sen University
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

ECOG 0-1
histologically confirmed non-keratinizing carcinoma (WHO type II or III) of nasal pharynx
stage III-IVa (AJCC/UICC 8th ), untreated NPC patients
NE≥ 1.5×10E9/L, HGB ≥ 100g/L and PLT ≥100×10E9/L
ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN

Exclusion Criteria

recurrent or metastatic NPC patients
histologically confirmed keratinizing carcinoma (WHO type I) of nasal pharynx
already received radiation or chemotherapy
pregnant or lactating women, or women of childbearing age without birth control
HIV (+)
had other cancers before
used immune checkpoint inhibitor(CTLA-4、PD-1、PD-L1 etc.) before
complications requiring long-term treatment with immunosuppressive drugs or systemic or local use of corticosteroids with immunosuppressive dose
with immune deficiency diseases, or a history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma in childhood who have completely relieved and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators cannot be included)
use of massive dose of glucocorticoids within 4 weeks before enrollment
laboratory test values do not meet relevant standards within 7 days before enrollment
significantly lower functions of heart, liver, lung, kidney and bone marrow
serious or uncontrolled medical diseases or infections
participating other clinical trial in the same time
HBsAg (+) and HBV DNA >1×10E3 copiers /mL
HCV (+) unless HCV RNA PCR(-)
with any other treatment contraindications
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note